Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016, ORY-1001, an LSD1 inhibitor, is now in Roche&#8217;s hands and the company is focusing on its newer programmes: clinical-stage ORY-2001, a dual LSD1/MAOB inhibitor for neurodegenerative diseases and ORY-3001, a selective LSD1 inhibitor, in advanced preclinical studies in non-cancer areas. We have incorporated the recent &#8364;18m equity raise into our valuation, which has increased to &#8364;308m.

Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016, ORY-1001, an LSD1 inhibitor, is now in Roche&#8217;s hands and the company is focusing on its newer programmes: clinical-stage ORY-2001, a dual LSD1/MAOB inhibitor for neurodegenerative diseases and ORY-3001, a selective LSD1 inhibitor, in advanced preclinical studies in non-cancer areas. We have incorporated the recent &#8364;18m equity raise into our valuation, which has increased to &#8364;308m.

Oryzon has two assets, ORY-1001 and ORY-2001, in the clinical stage of development, with ORY-3001 being investigated for oncology indications in the preclinical stage. While the most advanced, ORY-1001, is now in Roche&#8217;s hands, Oryzon has been making progress with the newer programmes. Data from the Phase I trial with ORY-2001 for Alzheimer&#8217;s disease (AD) will be announced by end March 2017 and fresh preclinical data from ORY-2001 studies support its potential in a second indication, multiple sclerosis (MS). We make minor adjustments to our valuation, increasing it slightly to &#8364;266m.

Oryzon has two assets, ORY-1001 and ORY-2001, in the clinical stage of development, with ORY-3001 being investigated for oncology indications in the preclinical stage. While the most advanced, ORY-1001, is now in Roche&#8217;s hands, Oryzon has been making progress with the newer programmes. Data from the Phase I trial with ORY-2001 for Alzheimer&#8217;s disease (AD) will be announced by end March 2017 and fresh preclinical data from ORY-2001 studies support its potential in a second indication, multiple sclerosis (MS). We make minor adjustments to our valuation, increasing it slightly to &#8364;266m.

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive headline results had been announced earlier. ORY-1001&rsquo;s further development is now in Roche&rsquo;s hands, which also initiated a Phase I trial in a new indication small cell lung cancer (SCLC). Recently Oryzon released preclinical data supporting ORY-2001&rsquo;s potential in multiple sclerosis (MS), which we now include in our valuation. All these developments led to an increase in our Oryzon&rsquo;s valuation to &euro;250m.

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive headline results had been announced earlier. ORY-1001&rsquo;s further development is now in Roche&rsquo;s hands, which also initiated a Phase I trial in a new indication small cell lung cancer (SCLC). Recently Oryzon released preclinical data supporting ORY-2001&rsquo;s potential in multiple sclerosis (MS), which we now include in our valuation. All these developments led to an increase in our Oryzon&rsquo;s valuation to &euro;250m.

Spain

Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.

Faes Farma, S.A. develops, manufactures and markets pharmaceutical products throughout Spain and, through its subsidiary, Laboratorios Vitoria S.A., in Portugal. The Company's principal prescription products combat cardiovascular, respiratory, central nervous system, musculoskeletal and osteoporosis related ailments.

Almirall SA is an international pharmaceutical company. The Company produces allergy and respiratory, cardiovascular, central nervous system, digestive, infectious disease, oncology, osteomuscular, pediatric, and urology  drugs.

Laboratorios Farmaceuticos Rovi SA is a specialty pharmaceutical company. The Company researches, develops, manufactures, and markets small molecule and specialty biologic drugs. Rovi's services include contract manufacturing of aseptic filling and packaging of small-volume parenterals in prefilled syringes and vials and provides temperature-controlled storage facilities.

Laboratorios Farmaceuticos ROVI (ROVI SM)

Helixmith Co., Ltd operates as a biotechnology company. The Company develops innovative biopharmaceuticals, novel biologics, herbal therapeutics, and other related products. Helixmith markets its products worldwide.

iNtRON Biotechnology, Inc. is a bio-venture developing bio-active agents targeting infectious organisms and driving its commercial use.

NIBEC Co Ltd. manufactures, researches, and develops medical and dental products.  The Company's products include a Bulyonghwa treatment of residual protein and teeth whitening products.

Tego Science,Inc. is a cell therapy company producing wound-healing skin cell theraphy products originating from human epithelial cells.

Karyopharm Therapeutics, Inc. provides biopharmaceutical products and services. The Company develops and discovers drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation through activity modulation of critical pathways. Karyopham Therapeutics serves the healthcare industry throughout the United States.

Actinogen Medical Limited operates as a biotechnology company. The Company focuses on the treatment of alzheimer's disease and mild cognitive impairment. Actinogen Medical develops a novel drug to treat the condition and other age-related neurodegenerative diseases.

CrystalGenomics Incorporation develops pharmaceutical and agricultural products by structure-based drug discovery technology.  The Company also provides structural proteomic analysis services for helping drug discovery process.

Cellectis SA is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells.

Transgene S.A is a biotechnology company. The Company develops therapeutic vaccines and oncolytic viruses against solid tumors (lung, liver, head & neck and colorectal cancers). In addition to clinical-stage immunotherapies, Transgene S.A. develops individualized therapeutic vaccines and multi-functional oncolytic viruses.

Bioporto A/S develops and markets antibody-based products, including tests to diagnose human disease.  The Company's developments include a test (NGAL) to diagnose and monitor acute kidney damage.

Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oryzon Genomics (ORY SM)

Maturing epigenetics portfolio

Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016,...

Edison Investment Research

New data further back MS indication

Oryzon has two assets, ORY-1001 and ORY-2001, in the clinical stage of development, with ORY-3001 being investigated for oncology indications in...

Edison Investment Research

Expanding clinical R&amp;D pipeline

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Maturing epigenetics portfolio

Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016,...

Edison Investment Research

New data further back MS indication

Oryzon has two assets, ORY-1001 and ORY-2001, in the clinical stage of development, with ORY-3001 being investigated for oncology indications in...

Edison Investment Research

Expanding clinical R&amp;amp;D pipeline

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive...

Edison Investment Research

Expanding clinical R&D pipeline